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Background: We examined the efficacy and toxicity of proton beam therapy (PBT) for treating advanced
cholangiocarcinoma.
Methods: The clinical data and outcomes of 28 cholangiocarcinoma patients treated with PBT between January
2009 and August 2011 were retrospectively examined. The Kaplan–Meier method was used to estimate overall
survival (OS), progression-free survival (PFS), and local control (LC) rates, and the log-rank test to analyze the effects
of different clinical and treatment variables on survival. Acute and late toxicities were assessed using the National
Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Results: The median age of the 17 male and 11 female patients was 71 years (range, 41 to 84 years; intrahepatic/
peripheral cholangiocarcinoma, n = 6; hilar cholangiocarcinoma/Klatskin tumor, n = 6; distal extrahepatic
cholangiocarcinoma, n = 3; gallbladder cancer, n = 3; local or lymph node recurrence, n = 10; size, 20–175 mm;
median 52 mm). The median radiation dose was 68.2 Gy (relative biological effectiveness [RBE]) (range, 50.6 to
80 Gy (RBE)), with delivery of fractions of 2.0 to 3.2 Gy (RBE) daily. The median follow-up duration was 12 months
(range, 3 to 29 months). Fifteen patients underwent chemotherapy and 8 patients, palliative biliary stent placement
prior to PBT. OS, PFS, and LC rates at 1 year were 49.0%, 29.5%, and 67.7%, respectively. LC was achieved in 6
patients, and was better in patients administered a biologically equivalent dose of 10 (BED10) > 70 Gy compared to
those administered < 70 Gy (83.1% vs. 22.2%, respectively, at 1 year). The variables of tumor size and performance
status were associated with survival. Late gastrointestinal toxicities grade 2 or greater were observed in 7 patients
<12 months after PBT. Cholangitis was observed in 11 patients and 3 patients required stent replacement.
Conclusions: Relatively high LC rates after PBT for advanced cholangiocarcinoma can be achieved by delivery of a
BED10 > 70 Gy. Gastrointestinal toxicities, especially those of the duodenum, are dose-limiting toxicities associated
with PBT, and early metastatic progression remains a treatment obstacle.
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Cholangiocarcinoma is a malignant tumor arising from
the epithelium of the bile ducts. It is estimated that
23,000 cases of cholangiocarcinoma are diagnosed in
Japan every year, an incidence higher than that in west-
ern countries [1]. Although surgery is the only poten-
tially curative treatment for cholangiocarcinoma, only* Correspondence: chioko-makita@live.jp
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reproduction in any medium, provided the or10% to 30% patients are candidates for surgery at pres-
entation [2]. The majority of patients present with either
locally advanced or distant metastatic disease. Even for
patients in whom curative resection is performed, the
prognosis remains poor; local failure rates are high, and
death from biliary obstruction, sepsis, and liver failure is
common. For patients with unresectable cholangiocarci-
noma, survival is poor, ranging from 3 to 9 months in
those receiving medical management alone due to tumor
aggressiveness [2-4].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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radiotherapy is controversial for several reasons [5]. These
include frequent local and regional recurrence despite
provision of definitive chemoradiotherapy; radiation in-
tolerance, which limits the dose that may be delivered to
the entire liver, proximal biliary tract, and digestive tract
[6]; and inability to deliver high dose X-rays to the tumor.
However, using charged-particle therapy, superior dose
distribution can be achieved due to the existence of the
Bragg peak, which enables delivery of higher doses of radi-
ation to tumor tissue without increasing exposure to the
surrounding normal tissue. Schoenthaler et al. reported
providing charged-particle therapy using helium and/
or neon to treat 22 patients with extrahepatic bile duct
carcinoma [7]. Improved median survival has been ob-
served in patients with microscopic residual disease
with the addition of adjuvant irradiation after charged-
particle therapy, also in comparison to patients treated
with conventional radiotherapy. Since January 2009,
advanced cholangiocarcinoma has been treated at our
institution with proton beam therapy (PBT), a form of
charge-particle therapy. Despite the potential of this
form of treatment, to our knowledge no other study has
examined its use in treating this patient population. To
fill this research gap, this study retrospectively evaluated
the efficacy and toxicity of PBT for the treatment of
unresectable and inoperable cholangiocarcinoma.
Methods
Patients
Between January 2009 and August 2011, 28 patients with
advanced cholangiocarcinoma (18 patients with unresect-
able cholangiocarcinoma and 10 with recurrent tumor
after surgery) were treated with PBT at our institution.
The initial workup for these patients had generally in-
cluded taking a medical history; performing a physical
examination; conducting laboratory testing for a compre-
hensive metabolic panel and measurement of complete
blood cell count, carcinoembryonic level, and carbohy-
drate antigen 19–9 level; and conducting chest X-ray, elec-
trocardiogram, computed tomography (CT) with positron
emission tomography (PET) using 2-(fluorine-18)-fluoro-
2-deoxy-D-glucose (FDG-PET/CT), enhanced abdominal
CT. Magnetic resonance imaging (MRI) was performed
on some patients to get additional information. Histo-
logical diagnosis of cholangiocarcinoma had been deter-
mined in all newly diagnosed patients prior to initiation of
PBT. Pathological diagnosis of recurrent cases had been
made prior to surgery.
Biopsy procedures had typically involved endoscopic
retrograde cholangiopancreatography with or without
endoscopic ultrasonography. Resectability had been de-
termined by individual hepatic surgeons. No evidence of
distant metastases had been found at the time of PBTinitiation in any patient. Abdominal surgical staging
had been performed in 1 patient, biliary stenting to re-
lieve symptoms in 8 patients with biliary obstruction,
ultrasound-guided percutaneous transhepatic biliary
drainage in 3 patients, and endoscopic retrograde bil-
iary drainage in 5 patients. Patients with carcinoma of
the ampulla of Vater were excluded from this study.
Treatment
All patients had undergone simulation using a 16-slice
large-bore helical CT scanner (Aquilion LB; Toshiba,
Tokyo, Japan) and a respiratory gating system (Anzai
Medical, Tokyo, Japan). Using this system, CT images
had been obtained in the exhalation phase, and a con-
ventional scan with a 2-mm slice thickness had been
obtained. A custom-induced vacuum-lock bag (Esform;
Engineering System Co., Matsumoto, Japan) had been
used for patient immobilization. Diagnostic CT or MRI
images had been fused with planning CT images for
target delineation. For PBT planning, a 3-dimensional
treatment planning system (Xio-M; CMS Japan, Tokyo,
Japan; Mitsubishi Electric Corporation, Kobe, Japan)
had been used. Gross tumor volume had been identified
from review of these images by the liver surgeon, gastro-
enterologist, and diagnostic radiologists.
The clinical target volume had included a 5- to 10-mm
radial expansion of the gross tumor volume to target
possible microscopic disease extension. Regional lymph
nodes had not been intentionally covered unless pa-
thologically enlarged. The planning target volume had
been expanded by 5 mm in all directions to create an
additional 5- to 7-mm margin in the craniocaudal direc-
tion to compensate for respiratory movements. The
photon plan was compared with the dose–volume histo-
gram, although conventional planning target volume is
not typically used in proton planning. The total dose at
the isocenter had been prescribed to cover 90% of the
planning target volume. Doses had been calculated on
the basis of the pencil beam algorithm. Proton energy
levels of 150 and 210 MeV for 1 to 4 portals had been
planned.
The PBT system (Proton Therapy System; Mitsubishi)
uses a synchrotron that could accelerate protons up to
235 MeV. A respiratory gating system (Anzai Medical,
Tokyo, Japan) had been used to synchronize treatment
in the expiratory phase. The relative biological effective-
ness of the proton beam had been determined to be 1.1.
The median radiation dose had been 68.2 Gy (relative
biological effectiveness [RBE]) (range, 50.6 to 80 Gy
(RBE)), with delivery of fractions of 2.0 to 3.2 Gy (RBE)
daily, depending on tumor location. In cases in which
the tumor had been adjacent to the digestive tract, a
dose of 2.0 to 2.2 Gy (RBE) per fraction had been deliv-
ered. In cases in which the tumor had been greater than
Table 1 Patient and tumor characteristics
N or range % or median
No. of patients 28 100
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*Eastern Cooperative Oncology Group; †carbohydrate antigen 19–9 level.
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dose of 3.2 Gy (RBE) per fraction had been delivered.
Follow-up and toxicity evaluation
Abdominal imaging studies (CT, MRI, or FDG-PET/CT)
and lab analyses (including measurement of tumor marker
levels) had been performed every 3 months after PBT
for the first 2 years. In cases in which obstructive jaun-
dice and hyperbilirubinemia had persisted after comple-
tion of PBT, additional radiological analyses had been
performed to evaluate local failure. In the subsequent
analysis of outcomes, local control (LC) was defined as
no sign of regrowth or new tumor development in the
target area. Acute and late toxicities were assessed using
the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0. To evaluate
post-treatment late toxicity in the duodenum, dose–volume
histograms were developed for cases delivered a BED of 3.
Statistical analysis
Observation of endpoints began on the same date on
which proton therapy was initiated. The Kaplan–Meier
method was used to estimate overall survival (OS),
progression-free survival (PFS), and LC and the log-
rank test to analyze the effects of different clinical and
treatment variables on survival. All statistical analyses
were performed using SPSS software version 18.0 (SPSS,
Chicago, IL, USA).
Ethical approval
This study was approved by an institutional committee of
Southern Tohoku Proton Therapy Center. The research
was in compliance with the Helsinki Declaration.
Results and discussion
Patient, tumor, and treatment characteristics
Table 1 lists the patient and tumor characteristics. The
median age of the 17 male and 11 female patients had
been 71 years (range, 41 to 84 years). Of the 28 patients,
6 had been newly diagnosed with intrahepatic cholangio-
carcinoma, 6 with hilar cholangiocarcinoma (Klatskin
tumor), 3 with distal extrahepatic cholangiocarcinoma,
and 3 with gallbladder cancer. Seven patients had experi-
enced local recurrence and 3 lymph node recurrence.
PBT had been administered to recurrent cases 12 to 40
months after surgery. Tumors treated with PBT had
ranged in size from 20 to 175 mm (median, 52 mm) in
the greatest dimension.
Table 2 lists the treatment characteristics of the patients
examined in this study. Because various fractionation regi-
mens had been used for treatment, a biologically equiva-
lent dose (BED) was calculated for comparison using the
linear–quadratic model. Assuming a BED of 10 (i.e.,
BED10; α/β = 10) for tumor control, the estimated medianBED10 had been 75.8 Gy (range, 61.7 to 105.6 Gy). As-
suming a BED of 3 (BED3; α/β = 3) for cases in which late
toxicity had been observed, the estimated median BED3
had been 106.8 Gy (range, 95.3 to 165.3 Gy). Chemother-
apy consisting of gemcitabine and/or tegafur, gimeracil,
and either oteracil (S-1) or cisplatin before or after PBT
had been administered to 15 patients, and S-1 had been
administered concurrently with PBT treatment to 3
patients.
Clinical outcomes
Among all patients, the median follow-up duration had
been 12 months (range, 3 to 29 months) and OS and PFS
at 1 year had been 49.0% (95% confidence interval [CI]
59.1% to 38.9%) and 29.5% (95% CI 39.3% to 19.7%), re-
spectively (Figure 1). Univariate analysis identified a sig-
nificant relationship between survival and the variables of
tumor size and performance status, but not between sur-
vival and the variables of age, gender, tumor markers, and
chemotherapy (Table 3). Of the 19 patients (67.9%) who
had experienced recurrence during the observation period,
Table 2 Patient treatment characteristics
N %





























S-1 + GEM 2 7
GEM + CDDP 1 4
BED, biologically effective dose; S-1, tegafur, gimeracil, and oteracil; CDDP,
cisplatin; RBE, relative biological effectiveness.
Figure 1 Overall survival and progression-free survival. Median
overall survival was 12.0 months and median progression-free
survival 8.0 months.
Table 3 Univariate analysis of factors potentially
affecting overall survival
n Median survival (months) p
Age (years)
≥70 14 10.0 0.034
<70 14 14.0 -
Sex
Male 17 12.0 0.339
Female 11 14.0 -
ECOG performance status
1 or 2 13 5 0.000
0 15 - -
Tumor size (mm)
>50 15 10.0 0.008
≤50 13 18.0 -
BED-10 (Gy)
>70 22 14.0 0.243
<70 6 5.0 -
CA19-9
>37 15 10.0 0.312
≤37 13 15.0 -
Chemotherapy
Yes 15 18.0 0.474
No 13 12.0 -
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tients (17.9%) new intrahepatic tumors, 5 patients (17.9%)
peritonitis carcinomatosa, 2 patients (7.1%) distant metas-
tases, and 1 patient (3.6%) lymph node metastases. Of the
16 patients (57.1%) who had died during the observation
period, the death of 14 patients (had been attributed to
cholangiocarcinoma; the death of 1 patient (3.6%) to
cholangitis-related disseminated intravascular coagulation
after replacement of the biliary stent, which had caused
perforation of the bile duct; and the death of 1 patient
(3.6%) to lung cancer. The LC rate at 1 year had been
67.7% (95% CI 79.1 to 56.3). Univariate analysis indicated
better LC in patients to whom a BED10 greater than
Table 4 Acute and late toxicities experienced during
observation period
Grade
Toxicity 1 2 3 4 5
Acute
Leucopenia 5 0 0 0 0
Anemia 2 0 0 0 0
Thrombocytopenia 1 1 0 0 0
Erythema 7 1 0 0 0
Nausea 3 0 0 0 0
Anorexia 7 2 0 0 0
Abdominal pain 3 1 0 0 0
Diarrhea 0 1 0 0 0
Cholangitis 1 3 1 0 0
Late
Cholangitis 0 4 2 0 0
Common bile duct stenosis 0 0 1 0 0
Gastric ulcer 0 1 0 0 0
Duodenal ulcer 0 1 1 0 0
Duodenal hemorrhage 0 0 2 0 0
Duodenal stenosis 0 1 1 0 0
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those to whom a BED10 less than 70 Gy had been
administered (83.1% vs. 22.2%, respectively, at 1 year;
p = 0.002) (Figure 2).
Toxicity
Table 4 lists the acute and late toxicities that had been
experienced by the patients. Eight patients had devel-
oped acute treatment-related toxicities of grade 2 or
greater in the forms of thrombocytopenia, erythema, an-
orexia, abdominal pain, diarrhea, and cholangitis. Six pa-
tients had developed late toxicities of cholangitis of
grade 2 or 3. One patient had been diagnosed with grade
2 common bile duct stenosis. All patients with acute and
late treatment-related cholangitis had been treated with
intravenous antibiotics, and 3 had required stent re-
placement. Late gastrointestinal toxicities of grade 2 or
greater had been experienced by 7 patients within 12
months after PBT in the forms of duodenal ulcer in 2 pa-
tients, duodenal hemorrhage in 2 patients, duodenal sten-
osis in 2 patients, and gastric ulcer in 1 patient. Of the 15
patients (53.6%) who had undergone irradiation of the
duodenum, the mean irradiated volume exceeding a BED3
of 80 Gy to the duodenum had been 11.0 ± 4.3 ml. Of the
6 patients who had experienced duodenal-related toxic-
ities, the mean irradiated volume exceeding a BED3 of
80 Gy to the duodenum had been 21.0 ± 5.1 ml.
In patients with unresectable cholangiocarcinoma, pallia-
tive irradiation following biliary decompression has beenFigure 2 Local control stratified according administration of
BED10 >70 Gy or < 70 Gy.shown to prolong survival [3]. Although patients with
postoperative local or regional recurrence are treated with
radiotherapy, no definitive treatment has yet been estab-
lished. Because no global consensus exists for treatment of
advanced cholangiocarcinoma, various palliative therapies
have been administered to attempt to improve survival
and quality of life, including external beam radiotherapy
(EBRT), brachytherapy, systemic chemotherapy, radio-
frequency ablation, and transarterial chemoembolization
[8,9]. Because of their ability to deliver markedly higher
doses of radiation directly to tumor tissue, intensity-
modulated radiotherapy and stereotactic body radiother-
apy have also been utilized [10,11].
Among the treatment options that have been exam-
ined, one study investigated therapy using charged parti-
cles, such as neon and helium ions, in the treatment of
extrahepatic bile duct carcinoma with microscopically
positive margins after surgery in 22 patients [7]. Deliver-
ing a total dose ranging from 4800 to 6778 cGy (median,
6000 cGy) with curative intent, a trend toward improved
outcome in patients treated with neon was observed,
with the median survival of these patients found to be
25 months compared to 12.5 months with helium and
11 months with photon therapy.
In an effort to maximize outcomes in patients with
advanced cholangiocarcinoma who are treated radio-
therapeutically, several studies have investigated the
presumed correlation between tumor dose and survival.
Alden and Mohiduddin reported an improvement in the
Makita et al. Radiation Oncology 2014, 9:26 Page 6 of 7
http://www.ro-journal.com/content/9/1/262-year survival rate (48% vs. 0%, p = 0.03) and median
survival duration (24 months vs. 6 months) with treat-
ment with EBRT and brachytherapy delivering total
doses greater than 55 Gy [12]. Valek et al. found that ad-
ministration of intraluminal brachytherapy significantly
prolonged survival and symptom-free duration in pa-
tients with unresectable cholangiocarcinoma who had
undergone stent replacement [13]. Improved LC and
OS have also been observed with higher radiation doses,
suggesting that dose escalation may be a promising
therapeutic approach. On the other hand, Crane et al.
found that the addition of brachytherapy provided no
benefit [14]. Although we did observe a better LC in pa-
tients administered a BED10 of greater than 70 Gy PBT
compared to those receiving a BED10 of less than 70 Gy
(89% vs. 36%, respectively, at 1 year), no survival benefit
was found with administration of a higher proton dose
in the current study.
The role of chemotherapy in treating cholangiocarci-
noma is unclear. Kopleson et al. asserted the feasibility
and potential benefit of chemotherapy in addition to ra-
diation [15]. Deodato et al. also reported that concurrent
chemotherapy with 5-fluorouracil appeared to improve
outcome based on observation of a median survival of
22 months and a 2-year survival rate of 41% [16]. In
contrast, Crane et al. found no survival benefit of con-
current chemoradiation [14]. In accordance with the find-
ings of Crane et al. [14], combined chemotherapy and
PBT was found to provide no survival benefits to the pa-
tients in the current study, in whom early metastatic pro-
gression of the liver, regional lymph nodes, and distant
lesions remained major treatment obstacles. Among all
patients in this study, 19 (67.9%) experienced tumor recur-
rence, with 13 (46.4%) of these 19 patients developing re-
current tumors outside of the proton-irradiated field,
among them the 7 patients who had been undergone
chemotherapy. Further study is needed to define the roles
of chemotherapy and PBT in cholangiocarcinoma.
Potential acute toxicities of combined EBRT and chemo-
therapy include nausea, vomiting, anorexia, dehydration,
skin reaction, gastritis, duodenitis, fatigue, and liver dys-
function [15-17]. In a study of a series of 81 patients with
extrahepatic cholangiocarcinoma who underwent com-
bined chemotherapy and radiotherapy, Ben-David et al.
observed development of late complications (ulcer forma-
tion, gastritis, and/or veno-occlusive disease of the liver)
in 5 patients with hilar carcinoma at a median of 6 months
after treatment [17]. Regarding the effect of volume on the
development of gastrointestinal toxicity, Emani et al. esti-
mated a dose of 1/3 for small bowel irradiation (i.e.,
50 Gy) based on the probability of a 5% complication
within the 5 years following irradiation (i.e., a tolerance
dose [TD] of 5/5). Emani et al.’s estimation remains a
commonly applied dose limit when small portions of thesmall bowel are treated with a conventional fraction. Des-
pite this estimation, the probability of a 50% complication
within the 5 years following irradiation (TD50/5) for par-
tial small bowel irradiation (i.e., delivery of 60 Gy) remains
unexplored [18]. The minimum tolerable radiation dose to
the duodenum that results in TD 5/5 is 50 Gy with frac-
tions of 1.8 Gy/day, a dose equivalent to a BED3 of 80 Gy.
Although duodenal complications were observed in 6
patients in the current study, 15 of the 28 patients
(53.6%) had undergone duodenal irradiation at a mean
volume of BED3 of >80 Gy of 11.0 ± 4.3 ml. In the 6 pa-
tients in whom duodenal toxicities occurred, the irradi-
ated volume to the duodenum (BED3 of >80 Gy) was
21.0 ± 5.1 ml. To minimize toxicity in patients with chol-
angiocarcinoma adjacent to the gastrointestinal tract, es-
pecially the duodenum, the irradiated volume of duodenal
irradiation should be decreased in PBT.
Due to limitations of the present study such as small
number of patients, heterogeneous doses, and retrospect-
ive nature, optimal PBT doses and chemotherapy regimen
are still unclear. But we indicate the potential benefit and
toxicity profile of PBT for advanced cholangiocarcinoma.
Further investigations are warranted.
Conclusion
In conclusion, the study results indicate that PBT is an
effective, as evidenced by the high LC rates of patients
administered a BED10 greater than 70 Gy, as well as feas-
ible, as evidenced by the tolerable toxicity levels of all pa-
tients except those 6 who experienced duodenal toxicity,
form of treatment for cholangiocarcinoma. Neverthe-
less, early metastatic progression remains a major obs-
tacle since PBT may not be effective in those cases.
Further study is needed to define the roles of chemo-
therapy and PBT in cholangiocarcinoma treatment.
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